Literature DB >> 19855952

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter].

U Grouven, L G Hemkens, R Bender, P T Sawicki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19855952     DOI： 10.1007/s00125-009-1582-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  9 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Competing risks as a multi-state model.

Authors:  Per Kragh Andersen; Steen Z Abildstrom; Susanne Rosthøj
Journal:  Stat Methods Med Res       Date:  2002-04       Impact factor: 3.021

3.  Registries for robust evidence.

Authors:  Nancy A Dreyer; Sarah Garner
Journal:  JAMA       Date:  2009-08-19       Impact factor: 56.272

4.  Insulin glargine and malignancy: an unwarranted alarm.

Authors:  Stuart J Pocock; Liam Smeeth
Journal:  Lancet       Date:  2009-07-17       Impact factor: 79.321

5.  [Prevalence of diabetes mellitus in the adult German population].

Authors:  W Thefeld
Journal:  Gesundheitswesen       Date:  1999-12

6.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

Authors:  P Kurtzhals; L Schäffer; A Sørensen; C Kristensen; I Jonassen; C Schmid; T Trüb
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

7.  Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine.

Authors:  J M Nagel; U Mansmann; K Wegscheider; J Röhmel
Journal:  Diabetologia       Date:  2009-09-24       Impact factor: 10.122

8.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

9.  Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.

Authors:  D Simon
Journal:  Diabetologia       Date:  2009-10-27       Impact factor: 10.122
  9 in total
  4 in total

Review 1.  Cardio-oncology Related to Heart Failure: Common Risk Factors Between Cancer and Cardiovascular Disease.

Authors:  Anne Blaes; Anna Prizment; Ryan J Koene; Suma Konety
Journal:  Heart Fail Clin       Date:  2017-04       Impact factor: 3.179

2.  The double trouble of metabolic diseases: the diabetes-cancer link.

Authors:  Slavica Tudzarova; Mahasin A Osman
Journal:  Mol Biol Cell       Date:  2015-09-15       Impact factor: 4.138

Review 3.  Pro-angiogenic Role of Insulin: From Physiology to Pathology.

Authors:  Carlos A Escudero; Kurt Herlitz; Felipe Troncoso; Katherine Guevara; Jesenia Acurio; Claudio Aguayo; Alejandro S Godoy; Marcelo González
Journal:  Front Physiol       Date:  2017-04-05       Impact factor: 4.566

4.  Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort.

Authors:  Rachel Dankner; Ran Balicer; Paolo Boffetta; Lital Keinan Boker; Sylvan Wallenstein; Laurence Freedman; Margalit Goldfracht; Jesse Roth; Ronald Tamler; Derek LeRoith
Journal:  BMC Cancer       Date:  2012-08-23       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.